FDA
-
-
-
-
-
-
-
Alkermes to present sleep medicine research at SLEEP 2026 conference
-
-
-
-
-
-
-
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
-
-
-
-
-
-
-
Alkermes plc Announces CEO Succession Plan
-
-
-
-
-
-
-
Avadel board deems Lundbeck's $2.4 billion bid superior to Alkermes deal
-
-
-
-
-
-
-
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
-
-
-
-
-
-
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
-
-
-
-
-
-
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
-
325,857 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

